p21 disrupts the interaction between cdk2 and the E2F-p130 complex

被引:0
|
作者
Shiyanov, P
Bagchi, S
Adami, G
Kokontis, J
Hay, N
Arroyo, M
Morozov, A
Raychaudhuri, P
机构
[1] UNIV ILLINOIS,DEPT BIOCHEM,CHICAGO,IL 60612
[2] UNIV ILLINOIS,COLL DENT,CHICAGO,IL 60612
[3] UNIV CHICAGO,BEN MAY INST,DEPT PHARMACOL & PHYSIOL SCI,CHICAGO,IL 60637
关键词
D O I
暂无
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
In nonproliferating or growth-arrested cells, the transcription factor E2F remains bound to the retinoblastoma-related protein p130. Accumulation of this E2F-p130 complex correlates with an arrest of the cell cycle progression. Progression through G(1) phase is associated with a cyclin-dependent binding of the cyclin-dependent kinase cdk2 to the E2F-p130 complex. By fractionating mouse L-cell extracts, we have obtained a partially purified preparation of the E2F-p130 complex that also contains cdk2. Incubation of this complex with recombinant p21 results in a disruption of the interaction between cdk2 and the E2F-p130 complex. We have also analyzed the interaction between cdk2 and the E2F-p130 complex in extracts of a cell line that expresses a temperature-sensitive mutant of p53. Incubation at the permissive temperature (32 degrees C) results in an induction of p21 synthesis. An increase in the level of p21 in these cells correlates with a loss of cdk2 from the cdk2-containing E2F-p130 complex. We also show that the expression of a reporter gene containing E2F sites in the promoter region is reduced by the coexpression of p21. Since p21 is believed to be a mediator of p53, we speculate that the p21-mediated disruption of the cdk2-containing E2F-p130 complex plays a role in the growth suppression function of p53.
引用
收藏
页码:737 / 744
页数:8
相关论文
共 50 条
  • [21] Complex mechanisms underlying impaired activation of Cdk4 and Cdk2 in replicative senescence: Roles of p16, p21, and cyclin D1
    Morisaki, H
    Ando, A
    Nagata, Y
    Pereira-Smith, O
    Smith, JR
    Ikeda, K
    Nakanishi, M
    EXPERIMENTAL CELL RESEARCH, 1999, 253 (02) : 503 - 510
  • [22] Methylglyoxal stimulated proliferation of vascular smooth muscle cells through p21/CDK2 pathway
    Chang, Tuanjie
    Wang, Rui
    Wu, Lingyun
    ACTA PHARMACOLOGICA SINICA, 2006, 27 : 406 - 406
  • [23] ISOLATION OF THE RB-RELATED P130 THROUGH ITS INTERACTION WITH CDK2 AND CYCLINS
    HANNON, GJ
    DEMETRICK, D
    BEACH, D
    GENES & DEVELOPMENT, 1993, 7 (12A) : 2378 - 2391
  • [24] p21 Is a critical CDK2 regulator essential for proliferation control in Rb-deficient cells
    Brugarolas, J
    Bronson, RT
    Jacks, T
    JOURNAL OF CELL BIOLOGY, 1998, 141 (02): : 503 - 514
  • [25] CDK2、p21和p27在生长激素腺瘤中的表达及CDK2抑制剂的体外应用
    梁丽
    李振业
    高华
    临床和实验医学杂志, 2019, 18 (16) : 1681 - 1684
  • [26] Increased level of p21 in human ovarian tumors is associated with increased expression of cdk2, cyclin A and PCNA
    Barboule, N
    Baldin, V
    Jozan, S
    Vidal, S
    Valette, A
    INTERNATIONAL JOURNAL OF CANCER, 1998, 76 (06) : 891 - 896
  • [27] Mdm2 is required for inhibition of Cdk2 activity by p21, thereby contributing to p53-dependent cell cycle arrest
    Giono, Luciana E.
    Manfredi, James J.
    MOLECULAR AND CELLULAR BIOLOGY, 2007, 27 (11) : 4166 - 4178
  • [28] MicroRNA-3619-5p suppresses bladder carcinoma progression by directly targeting β-catenin and CDK2 and activating p21
    Zhang, Qingsong
    Miao, Shuo
    Han, Xihong
    Li, Chuanchang
    Zhang, Mengyang
    Cui, Kai
    Xiong, Tao
    Chen, Zhong
    Wang, Chenghe
    Xu, Hua
    CELL DEATH & DISEASE, 2018, 9
  • [29] MicroRNA-3619-5p suppresses bladder carcinoma progression by directly targeting β-catenin and CDK2 and activating p21
    Qingsong Zhang
    Shuo Miao
    Xihong Han
    Chuanchang Li
    Mengyang Zhang
    Kai Cui
    Tao Xiong
    Zhong Chen
    Chenghe Wang
    Hua Xu
    Cell Death & Disease, 9
  • [30] Induction of cell cycle arrest via the p21, p27-cyclin E,A/Cdk2 pathway in SMMC-7721 hepatoma cells by clioquinol
    Huang, Zhiwei
    Wang, Lianqiu
    Chen, Lifeng
    Zhang, Yifei
    Shi, Ping
    ACTA PHARMACEUTICA, 2015, 65 (04) : 463 - 471